Centiva Capital LP Purchases Shares of 10,561 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Centiva Capital LP bought a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,561 shares of the life sciences company’s stock, valued at approximately $192,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Blue Trust Inc. raised its position in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares in the last quarter. CWM LLC lifted its stake in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 425 shares during the last quarter. KBC Group NV raised its holdings in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after buying an additional 1,120 shares during the period. Canada Pension Plan Investment Board purchased a new position in Integra LifeSciences during the second quarter worth $114,000. Finally, Northwest Investment Counselors LLC bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth about $73,000. Institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

IART has been the topic of several recent analyst reports. Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Finally, Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $23.00.

Insider Activity at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.10% of the stock is owned by insiders.

Integra LifeSciences Trading Up 0.4 %

Shares of IART stock opened at $24.24 on Friday. The stock has a 50 day simple moving average of $21.98 and a 200-day simple moving average of $23.79. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -269.33, a PEG ratio of 0.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same period in the previous year, the business earned $0.76 EPS. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.